December 16, 2021
Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma
December 14, 2021
Sattva S. Neelapu, MD, spoke about which abstracts he was most excited to see presented at the upcoming American Society of Hematology Annual Meeting.
December 12, 2021
Sattva S. Neelapu, MD, spoke about the ZUMA-5 trial and the long-term follow-up results seen with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.